A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2002
11/18/2002	CA2381829A1 A method for tumor treatment with fumagillol derivatives
11/18/2002	CA2381637A1 Compositions and methods for treating or preventing convulsions or seizures
11/15/2002	WO2001087875A1 Novel benzofuran derivatives
11/15/2002	CA2409096A1 Novel benzofuran derivatives
11/14/2002	WO2002090981A1 Antitumor antigen against htlv-1 tumor or antigen epitope thereof
11/14/2002	WO2002090600A2 A method for regulating immune function in primates using the foxp3 protein
11/14/2002	WO2002090566A2 Recombinant tumor specific antibody and use thereof
11/14/2002	WO2002090558A1 Novel expression vectors and uses thereof
11/14/2002	WO2002090555A1 A method for transfection of rna using electrical pulses
11/14/2002	WO2002090546A1 Polypeptide serving as angiogenic marker and dna thereof
11/14/2002	WO2002090530A2 Kinases and phosphatases
11/14/2002	WO2002090520A2 Toll/interleukin-1 receptor adaptor protein (tirap)
11/14/2002	WO2002090514A2 Epidermal growth factor receptorantisense oligonucleotides
11/14/2002	WO2002090504A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
11/14/2002	WO2002090387A1 Reproductive cancer diagnosis and therapy
11/14/2002	WO2002090382A2 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof
11/14/2002	WO2002090361A1 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic
11/14/2002	WO2002090358A1 Disubstituted 7,9-guaninium halides as telomerase inhibitors
11/14/2002	WO2002090357A1 Disubstituted 1,7-guanines
11/14/2002	WO2002090355A1 N-aroyl cyclic amines
11/14/2002	WO2002090352A2 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
11/14/2002	WO2002090349A1 N-oxide anthranylamide derivatives and their use as medicaments
11/14/2002	WO2002090346A1 Phthalazine derivatives with angiogenesis inhibiting activity
11/14/2002	WO2002090334A1 Isoquinolinone derivatives as parp inhibitors
11/14/2002	WO2002090326A1 Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists
11/14/2002	WO2002090325A2 Benzazepinone alpha v integrin receptor antagonists
11/14/2002	WO2002090313A1 Aloe-emodin derivatives and their use in the treatment of neoplastic pathologies
11/14/2002	WO2002089919A2 Usage of zinc for preventing tnf-induced pathology during cancer therapy
11/14/2002	WO2002089858A1 Azo compounds for type i phototherapy
11/14/2002	WO2002089842A1 Combination therapy using anti-egfr antibodies and anti-hormonal agents
11/14/2002	WO2002089836A1 Cancer metastasis interfering vaccine
11/14/2002	WO2002089832A2 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
11/14/2002	WO2002089829A2 Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer
11/14/2002	WO2002089824A1 Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof
11/14/2002	WO2002089819A1 Glycoconjugates and uses thereof
11/14/2002	WO2002089802A2 Use of neurokinin receptor antagonists to treat androgen-dependent diseases
11/14/2002	WO2002089801A1 Use of benzothiophenes to treat and prevent prostave cancer
11/14/2002	WO2002089800A2 N-aroyl cyclic amine derivatives as orexin receptor antagonists
11/14/2002	WO2002089795A1 Method for treatment of tumors using nordihydroguaiaretic acid derivatives
11/14/2002	WO2002089789A1 Trimethyl lock based tetrapartate prodrugs
11/14/2002	WO2002089787A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	WO2002089782A2 Dioxanes and uses thereof
11/14/2002	WO2002089776A1 Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof
11/14/2002	WO2002089768A1 Liquid injectable formulation of disodium pamidronate
11/14/2002	WO2002089747A2 Compositions and methods for the therapy and diagnosis of prostate cancer
11/14/2002	WO2002076476A3 Prodrugs of anticancer agents employing substituted aromatic acids
11/14/2002	WO2002072577A3 Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors.
11/14/2002	WO2002068457A3 Antiangiogenic peptides derived from endostatin
11/14/2002	WO2002067913A8 (z)-styrylbenzylsulfones and pharmaceutical uses thereof
11/14/2002	WO2002066028A3 Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids
11/14/2002	WO2002064616A3 Agonists and antagonists of sphingosine-1-phosphate receptors
11/14/2002	WO2002049634A3 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
11/14/2002	WO2002028906A3 Regulation of human sphingosine kinase-like protein
11/14/2002	WO2002018623A3 Methods and reagents for protease inhibition
11/14/2002	WO2002018404A3 Nucleoside derivatives for the treatment of hepatitis c
11/14/2002	WO2002011530A9 Transgenic animal
11/14/2002	WO2001062235A3 A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
11/14/2002	WO2001035106A3 Methods for identifying and using amyloid-inhibitory compounds
11/14/2002	WO2001031036A9 Modified viral surface proteins which bind to cells of tumor vasculature
11/14/2002	WO2001019842A9 Subunit optimized fusion proteins
11/14/2002	US20020169439 Modular infusion device and method
11/14/2002	US20020169314 Sulfonamide derivative as a matrix metalloproteinase inhibitor
11/14/2002	US20020169292 Human glycoprotein hormone for use in the prevention and treatment of metabolic and sexual disorders
11/14/2002	US20020169291 Interleukin-18 mutants, their production and use
11/14/2002	US20020169209 Potentiation of therapeutic effects of fatty acids
11/14/2002	US20020169203 Modulators of all three classes of calcium channel blocker subtypes (Small, Intermediate and Big conductance K channel (SK, IK and BK)) comprising malonate esters and nitriles; respiratory, brain, cardiovascular, urogenital disorders
11/14/2002	US20020169202 Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same
11/14/2002	US20020169200 Antitumor, antiinflammatory and antiarthritic agents, treating metastasis, restenosis, osteoporosis, inflammation, macular degeneration, and diabetic retinopathy
11/14/2002	US20020169198 Agonists of the progesterone receptor; contraceptives, hormone replacement therapy and treating menopause symptoms
11/14/2002	US20020169190 Dosing schedule of antitumor agents
11/14/2002	US20020169180 Quinoline or quinazoline derivatives; antitumor agent, treating respiratory tract and gastrointestinal disorders
11/14/2002	US20020169177 Imidazole and benzimidazole caspase inhibitors and uses thereof
11/14/2002	US20020169176 Method for inhibiting retinoid skin damage
11/14/2002	US20020169174 Xanthine phosphodiesterase V inhibitors
11/14/2002	US20020169165 Substituted bicyclic derivatives for the treatment of abnormal cell growth
11/14/2002	US20020169164 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
11/14/2002	US20020169160 Sulfonamide matrix metalloproteinase inhibitors
11/14/2002	US20020169159 An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor
11/14/2002	US20020169154 Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
11/14/2002	US20020169150 Hormone replacement therapy
11/14/2002	US20020169144 Angiogenesis inhibition
11/14/2002	US20020169143 Methods and products related to low molecular weight heparin
11/14/2002	US20020169141 Potentiates the coadministration of irinotecan
11/14/2002	US20020169140 Minimising dosage required of chemotherapeutic agents for their use in antiviral, antibacterial, antiparasitic and anticancer chemotherapy; for treating neoplasms and tumours, viral, bacterial, or parasite infections
11/14/2002	US20020169135 Administration of a G1 and/or S phase drug, which is preferably beta-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel
11/14/2002	US20020169132 Polypeptides
11/14/2002	US20020169131 TGF-alpha polypeptides, functional fragments and methods of use therefor
11/14/2002	US20020169128 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
11/14/2002	US20020169114 Formulation of boronic acid compounds
11/14/2002	US20020169110 Diagnosis of metastatic cancer by the mts-1 gene
11/14/2002	US20020168764 Generation and recovering of preferential viral particles; obtain cells, infect with virus, extract virus from cells using detergent, recover virus
11/14/2002	US20020168763 Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
11/14/2002	US20020168740 Kinase for use in the treatment of inflammation, viral infection, cancer, sepsis, psoriasis and restenosis
11/14/2002	US20020168716 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of tumors, immunological, autoimmune, skin, viral, bone, nervous system and inflammatory disorders
11/14/2002	US20020168712 Molecules designated LDCAM
11/14/2002	US20020168710 Anticancer agents; cardiovascular disorders; anticholesterol agents
11/14/2002	US20020168695 Detecting cell proliferative disorder in humans; obtain tissue sample, incubate with probe, detect signal from tissue sample, signal indicates cancer
11/14/2002	US20020168672 Nucleotide sequences coding proteins for use in the treatment of tumors
11/14/2002	US20020168650 Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
11/14/2002	US20020168647 Compositions and methods for the therapy and diagnosis of head and neck cancer

1 ... 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 ... 2211